New data shows the state of New Mexico earned US$24.1 million in revenue from medical cannabis during the first quarter of 2018, a 27-percent increase from the same period last year.

Ultra Health, a dispensary operator in the US market, issued a report on the performance of patient revenues from the New Mexico Medical Cannabis Program in the state.

According to the information presented by Ultra Health, retail sales averaged US$689,298 per producer for the quarter, while the median amounted to US$419,945.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Patient population continued to increase as well, with 4,300 new patients added during Q1 2018. As of March 31, patient enrolment in New Mexico had reached 50,954 active legal cannabis users.

“As the decade-old New Mexico Medical Cannabis Program matures, the leading competitors are strengthening market share which likely will accelerate consolidation in the industry,” Ultra Health wrote.

State working towards complete legalization

New Mexico has had a medical cannabis bill since 2007. The state is now preparing to completely legalize the drug by asking state voters to decide on the issue.

“Marijuana prohibition in New Mexico has clearly failed,” said Emily Kaltenbach, New Mexico state director with the Drug Policy Alliance, after the bill to tax and regulate the drug passed the Senate Rules Committee in the state.

“It hasn’t reduced use and instead has resulted in mass criminalization, appalling racial disparities, and enormous fiscal waste,” Kaltenbach added.

The data from Ultra Health indicates the top five producers of cannabis in the state secured 44 percent of patient sales during this past quarter. Ultra Health states that the largest retail product remains cannabis flower, with a reported 3,427 pounds sold during the first quarter of 2018.

The report also includes a cannabis market development projection for New Mexico, with a calculation of over US$105 million in revenue for 2018 thanks to a patient count of 65,000 by the end of the year.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less